Which has preferable valuation & earnings, NVCT or HCM?

HUTCHMED has higher revenue and earnings than Nuvectis Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuvectis Pharma N/A N/A -$26.44M -$1.31 N/A HUTCHMED $548.51M 3.59 $456.91M N/A N/A

Is NVCT or HCM more profitable?

HUTCHMED's return on equity of 0.00% beat Nuvectis Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Nuvectis Pharma N/A -161.00% -98.88% HUTCHMED N/A N/A N/A

Which has better valuation and earnings, NVCT or TYRA?

Tyra Biosciences is trading at a lower price-to-earnings ratio than Nuvectis Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuvectis Pharma N/A N/A -$26.44M -$1.31 N/A Tyra Biosciences N/A N/A -$119.95M -$2.18 N/A

Is NVCT or TYRA more profitable?

Tyra Biosciences' return on equity of -42.66% beat Nuvectis Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Nuvectis Pharma N/A -161.00% -98.88% Tyra Biosciences N/A -42.66% -39.79%

Which has stronger earnings & valuation, RAPP or NVCT?

Rapport Therapeutics is trading at a lower price-to-earnings ratio than Nuvectis Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rapport Therapeutics N/A N/A -$111.48M -$2.60 N/A Nuvectis Pharma N/A N/A -$26.44M -$1.31 N/A

Is RAPP or NVCT more profitable?

Rapport Therapeutics' return on equity of -24.78% beat Nuvectis Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Rapport Therapeutics N/A -24.78% -23.44% Nuvectis Pharma N/A -161.00% -98.88%

Is NVCT or AMLX more profitable?

Amylyx Pharmaceuticals' return on equity of -55.69% beat Nuvectis Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Nuvectis Pharma N/A -161.00% -98.88% Amylyx Pharmaceuticals N/A -55.69% -50.73%

Nuvectis Pharma (NVCT) Competitors

$18.68 +0.65 (+3.58%)

As of 10:16 AM Eastern

Compare

NVCT vs. HCM, TYRA, RAPP, AMLX, and URGN

Should you buy Nuvectis Pharma stock or one of its competitors? MarketBeat compares Nuvectis Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nuvectis Pharma include HUTCHMED (HCM), Tyra Biosciences (TYRA), Rapport Therapeutics (RAPP), Amylyx Pharmaceuticals (AMLX), and Urogen Pharma (URGN). These companies are all part of the "pharmaceutical products" industry.

How does Nuvectis Pharma compare to HUTCHMED?

Nuvectis Pharma (NASDAQ:NVCT) and HUTCHMED (NASDAQ:HCM) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk, institutional ownership and media sentiment.

In the previous week, HUTCHMED had 2 more articles in the media than Nuvectis Pharma. MarketBeat recorded 2 mentions for HUTCHMED and 0 mentions for Nuvectis Pharma. HUTCHMED's average media sentiment score of 1.18 beat Nuvectis Pharma's score of 0.00 indicating that HUTCHMED is being referred to more favorably in the news media.

Company	Overall Sentiment
Nuvectis Pharma	Neutral
HUTCHMED	Positive

Nuvectis Pharma has a beta of -0.24, meaning that its stock price is 124% less volatile than the broader market. Comparatively, HUTCHMED has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market.

HUTCHMED has higher revenue and earnings than Nuvectis Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A
HUTCHMED	$548.51M	3.59	$456.91M	N/A	N/A

Nuvectis Pharma presently has a consensus target price of $35.00, suggesting a potential upside of 87.42%. HUTCHMED has a consensus target price of $15.30, suggesting a potential upside of 35.58%. Given Nuvectis Pharma's higher probable upside, analysts plainly believe Nuvectis Pharma is more favorable than HUTCHMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
HUTCHMED	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40

HUTCHMED's return on equity of 0.00% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvectis Pharma	N/A	-161.00%	-98.88%
HUTCHMED	N/A	N/A	N/A

96.8% of Nuvectis Pharma shares are owned by institutional investors. Comparatively, 8.8% of HUTCHMED shares are owned by institutional investors. 28.6% of Nuvectis Pharma shares are owned by insiders. Comparatively, 3.6% of HUTCHMED shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

HUTCHMED beats Nuvectis Pharma on 9 of the 13 factors compared between the two stocks.

How does Nuvectis Pharma compare to Tyra Biosciences?

Nuvectis Pharma (NASDAQ:NVCT) and Tyra Biosciences (NASDAQ:TYRA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Tyra Biosciences' return on equity of -42.66% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvectis Pharma	N/A	-161.00%	-98.88%
Tyra Biosciences	N/A	-42.66%	-39.79%

Nuvectis Pharma has a beta of -0.24, indicating that its stock price is 124% less volatile than the broader market. Comparatively, Tyra Biosciences has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market.

Nuvectis Pharma currently has a consensus price target of $35.00, indicating a potential upside of 87.42%. Tyra Biosciences has a consensus price target of $47.00, indicating a potential upside of 50.40%. Given Nuvectis Pharma's higher probable upside, equities research analysts clearly believe Nuvectis Pharma is more favorable than Tyra Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Tyra Biosciences	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87

In the previous week, Tyra Biosciences had 3 more articles in the media than Nuvectis Pharma. MarketBeat recorded 3 mentions for Tyra Biosciences and 0 mentions for Nuvectis Pharma. Tyra Biosciences' average media sentiment score of 0.30 beat Nuvectis Pharma's score of 0.00 indicating that Tyra Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Nuvectis Pharma	Neutral
Tyra Biosciences	Neutral

96.8% of Nuvectis Pharma shares are owned by institutional investors. Comparatively, 84.1% of Tyra Biosciences shares are owned by institutional investors. 28.6% of Nuvectis Pharma shares are owned by company insiders. Comparatively, 12.5% of Tyra Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Tyra Biosciences is trading at a lower price-to-earnings ratio than Nuvectis Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A
Tyra Biosciences	N/A	N/A	-$119.95M	-$2.18	N/A

Summary

Tyra Biosciences beats Nuvectis Pharma on 8 of the 14 factors compared between the two stocks.

How does Nuvectis Pharma compare to Rapport Therapeutics?

Rapport Therapeutics (NASDAQ:RAPP) and Nuvectis Pharma (NASDAQ:NVCT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership and valuation.

In the previous week, Rapport Therapeutics had 5 more articles in the media than Nuvectis Pharma. MarketBeat recorded 5 mentions for Rapport Therapeutics and 0 mentions for Nuvectis Pharma. Rapport Therapeutics' average media sentiment score of 0.64 beat Nuvectis Pharma's score of 0.00 indicating that Rapport Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Rapport Therapeutics	Positive
Nuvectis Pharma	Neutral

Rapport Therapeutics' return on equity of -24.78% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rapport Therapeutics	N/A	-24.78%	-23.44%
Nuvectis Pharma	N/A	-161.00%	-98.88%

Rapport Therapeutics is trading at a lower price-to-earnings ratio than Nuvectis Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rapport Therapeutics	N/A	N/A	-$111.48M	-$2.60	N/A
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A

96.8% of Nuvectis Pharma shares are held by institutional investors. 12.5% of Rapport Therapeutics shares are held by company insiders. Comparatively, 28.6% of Nuvectis Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Rapport Therapeutics currently has a consensus target price of $57.86, suggesting a potential upside of 39.84%. Nuvectis Pharma has a consensus target price of $35.00, suggesting a potential upside of 87.42%. Given Nuvectis Pharma's higher possible upside, analysts plainly believe Nuvectis Pharma is more favorable than Rapport Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Rapport Therapeutics has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market. Comparatively, Nuvectis Pharma has a beta of -0.24, suggesting that its stock price is 124% less volatile than the broader market.

Summary

Rapport Therapeutics beats Nuvectis Pharma on 8 of the 14 factors compared between the two stocks.

How does Nuvectis Pharma compare to Amylyx Pharmaceuticals?

Nuvectis Pharma (NASDAQ:NVCT) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk, media sentiment and valuation.

Nuvectis Pharma currently has a consensus price target of $35.00, indicating a potential upside of 87.42%. Amylyx Pharmaceuticals has a consensus price target of $24.63, indicating a potential upside of 34.67%. Given Nuvectis Pharma's higher possible upside, equities research analysts plainly believe Nuvectis Pharma is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

Amylyx Pharmaceuticals' return on equity of -55.69% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvectis Pharma	N/A	-161.00%	-98.88%
Amylyx Pharmaceuticals	N/A	-55.69%	-50.73%

In the previous week, Amylyx Pharmaceuticals had 5 more articles in the media than Nuvectis Pharma. MarketBeat recorded 5 mentions for Amylyx Pharmaceuticals and 0 mentions for Nuvectis Pharma. Amylyx Pharmaceuticals' average media sentiment score of 0.73 beat Nuvectis Pharma's score of 0.00 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Nuvectis Pharma	Neutral
Amylyx Pharmaceuticals	Positive

Nuvectis Pharma has a beta of -0.24, suggesting that its stock price is 124% less volatile than the broader market. Comparatively, Amylyx Pharmaceuticals has a beta of -0.2, suggesting that its stock price is 120% less volatile than the broader market.

Nuvectis Pharma has higher earnings, but lower revenue than Amylyx Pharmaceuticals. Nuvectis Pharma is trading at a lower price-to-earnings ratio than Amylyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A
Amylyx Pharmaceuticals	$87.37M	23.27	-$144.74M	-$1.50	N/A

96.8% of Nuvectis Pharma shares are owned by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. 28.6% of Nuvectis Pharma shares are owned by company insiders. Comparatively, 10.9% of Amylyx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Amylyx Pharmaceuticals beats Nuvectis Pharma on 10 of the 15 factors compared between the two stocks.

How does Nuvectis Pharma compare to Urogen Pharma?

Nuvectis Pharma (NASDAQ:NVCT) and Urogen Pharma (NASDAQ:URGN) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

Nuvectis Pharma has a net margin of 0.00% compared to Urogen Pharma's net margin of -94.83%. Urogen Pharma's return on equity of 0.00% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvectis Pharma	N/A	-161.00%	-98.88%
Urogen Pharma	-94.83%	N/A	-62.85%

Nuvectis Pharma has higher earnings, but lower revenue than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Nuvectis Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A
Urogen Pharma	$109.79M	18.94	-$153.49M	-$2.75	N/A

Nuvectis Pharma has a beta of -0.24, meaning that its share price is 124% less volatile than the broader market. Comparatively, Urogen Pharma has a beta of 1.56, meaning that its share price is 56% more volatile than the broader market.

Nuvectis Pharma currently has a consensus target price of $35.00, suggesting a potential upside of 87.42%. Urogen Pharma has a consensus target price of $41.57, suggesting a potential downside of 2.58%. Given Nuvectis Pharma's higher probable upside, equities research analysts plainly believe Nuvectis Pharma is more favorable than Urogen Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Urogen Pharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

In the previous week, Urogen Pharma had 6 more articles in the media than Nuvectis Pharma. MarketBeat recorded 6 mentions for Urogen Pharma and 0 mentions for Nuvectis Pharma. Urogen Pharma's average media sentiment score of 0.47 beat Nuvectis Pharma's score of 0.00 indicating that Urogen Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Nuvectis Pharma	Neutral
Urogen Pharma	Neutral

96.8% of Nuvectis Pharma shares are held by institutional investors. Comparatively, 91.3% of Urogen Pharma shares are held by institutional investors. 28.6% of Nuvectis Pharma shares are held by insiders. Comparatively, 4.8% of Urogen Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Urogen Pharma beats Nuvectis Pharma on 9 of the 16 factors compared between the two stocks.

Get Nuvectis Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NVCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NVCT vs. The Competition

Export

Metric	Nuvectis Pharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$495.18M	$3.64B	$6.80B	$12.37B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-14.25	20.71	27.09	24.07
Price / Sales	N/A	302.58	520.26	91.86
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	25.94	7.99	10.64	6.20
Net Income	-$26.44M	$23.81M	$3.60B	$331.63M
7 Day Performance	2.10%	-1.92%	-1.41%	-1.54%
1 Month Performance	35.13%	1.88%	0.97%	-1.17%
1 Year Performance	134.02%	43.58%	24.23%	17.81%

Nuvectis Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NVCT Nuvectis Pharma	3.455 of 5 stars	$18.68 +3.6%	$35.00 +87.4%	+131.2%	$495.18M	N/A	N/A	8
HCM HUTCHMED	2.1779 of 5 stars	$11.25 +1.0%	$15.30 +36.0%	-35.6%	$1.94B	$548.51M	N/A	1,796	Positive News Gap Up
TYRA Tyra Biosciences	2.4201 of 5 stars	$32.88 +0.6%	$47.00 +42.9%	+198.9%	$1.94B	N/A	N/A	20	News Coverage
RAPP Rapport Therapeutics	2.7317 of 5 stars	$41.46 +2.1%	$57.86 +39.5%	+173.9%	$1.94B	N/A	N/A	N/A
AMLX Amylyx Pharmaceuticals	3.1546 of 5 stars	$18.20 +4.5%	$24.25 +33.2%	+109.2%	$1.94B	$87.37M	N/A	200	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NVCT) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nuvectis Pharma (NVCT) Competitors

NVCT vs. HCM, TYRA, RAPP, AMLX, and URGN

How does Nuvectis Pharma compare to HUTCHMED?

Summary

How does Nuvectis Pharma compare to Tyra Biosciences?

Summary

How does Nuvectis Pharma compare to Rapport Therapeutics?

Summary

How does Nuvectis Pharma compare to Amylyx Pharmaceuticals?

Summary

How does Nuvectis Pharma compare to Urogen Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVCT vs. The Competition

Nuvectis Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nuvectis Pharma (NVCT) Competitors

NVCT vs. HCM, TYRA, RAPP, AMLX, and URGN

How does Nuvectis Pharma compare to HUTCHMED?

Does the media refer more to NVCT or HCM?

Which has more risk & volatility, NVCT or HCM?

Which has preferable valuation & earnings, NVCT or HCM?

Do analysts prefer NVCT or HCM?

Is NVCT or HCM more profitable?

Do institutionals & insiders hold more shares of NVCT or HCM?

Summary

How does Nuvectis Pharma compare to Tyra Biosciences?

Is NVCT or TYRA more profitable?

Which has more risk and volatility, NVCT or TYRA?

Do analysts recommend NVCT or TYRA?

Does the media favor NVCT or TYRA?

Do insiders & institutionals believe in NVCT or TYRA?

Which has better valuation and earnings, NVCT or TYRA?

Summary

How does Nuvectis Pharma compare to Rapport Therapeutics?

Does the media prefer RAPP or NVCT?

Is RAPP or NVCT more profitable?

Which has stronger earnings & valuation, RAPP or NVCT?

Do institutionals and insiders hold more shares of RAPP or NVCT?

Do analysts recommend RAPP or NVCT?

Which has more volatility and risk, RAPP or NVCT?

Summary

How does Nuvectis Pharma compare to Amylyx Pharmaceuticals?

Do analysts rate NVCT or AMLX?

Is NVCT or AMLX more profitable?

Does the media favor NVCT or AMLX?

Which has more volatility and risk, NVCT or AMLX?

Which has higher valuation and earnings, NVCT or AMLX?

Do institutionals & insiders believe in NVCT or AMLX?

Summary

How does Nuvectis Pharma compare to Urogen Pharma?

Is NVCT or URGN more profitable?

Which has higher earnings and valuation, NVCT or URGN?

Which has more risk and volatility, NVCT or URGN?

Do analysts prefer NVCT or URGN?

Does the media favor NVCT or URGN?

Do institutionals and insiders believe in NVCT or URGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVCT vs. The Competition

Nuvectis Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools